Literature DB >> 19635995

Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.

Sanjiv S Agarwala, Robert J Gray, Michael K K Wong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19635995     DOI： 10.1200/JCO.2009.23.0334

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

Authors:  Sanjiv S Agarwala; Sandra J Lee; Waiki Yip; Uma N Rao; Ahmad A Tarhini; Gary I Cohen; Douglas S Reintgen; Terry L Evans; Joanna M Brell; Mark R Albertini; Michael B Atkins; Shaker R Dakhil; Robert M Conry; Jeffrey A Sosman; Lawrence E Flaherty; Vernon K Sondak; William E Carson; Michael G Smylie; Alberto S Pappo; Richard F Kefford; John M Kirkwood
Journal:  J Clin Oncol       Date:  2017-01-30       Impact factor: 44.544

2.  Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.

Authors:  Paolo A Ascierto; Maria Napolitano; Egidio Celentano; Ester Simeone; Giusy Gentilcore; Antonio Daponte; Mariaelena Capone; Corrado Caracò; Rosa Calemma; Gerardo Beneduce; Margherita Cerrone; Vincenzo De Rosa; Giuseppe Palmieri; Giuseppe Castello; John M Kirkwood; Francesco M Marincola; Nicola Mozzillo
Journal:  J Transl Med       Date:  2010-08-16       Impact factor: 5.531
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.